These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26068628)

  • 61. [Therapeutic significance of sunitinib-induced "off-target" side effects].
    Maráz A; Cserháti A; Uhercsák G; Szilágyi E; Varga Z; Kahán Z
    Magy Onkol; 2014 Sep; 58(3):167-72. PubMed ID: 25260080
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
    P J G; A M; L M; H J H; M K; S B; N M
    Urol Oncol; 2014 Apr; 32(3):362-70. PubMed ID: 24321255
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
    Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
    Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
    Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
    Beuselinck B; Wolter P; Karadimou A; Elaidi R; Dumez H; Rogiers A; Van Cann T; Willems L; Body JJ; Berkers J; Van Poppel H; Lerut E; Debruyne P; Paridaens R; Schöffski P
    Br J Cancer; 2012 Nov; 107(10):1665-71. PubMed ID: 23132391
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
    Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H;
    Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
    Wendel C; Campitiello M; Plastino F; Eid N; Hennequin L; Quétin P; Longo R
    Am J Case Rep; 2017 Jan; 18():7-11. PubMed ID: 28044054
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.
    Ravaud A; Gomez-Roca C; Picat MQ; Digue L; Chevreau C; Gimbert A; Chauzit E; Sitta R; Cornelis F; Asselineau J; Aziza R; Daste A; Quemener C; Baud J; Bikfalvi A; Pedenon-Périchout D; Doussau A; Molimard M; Delord JP
    Eur J Cancer; 2017 Nov; 85():39-48. PubMed ID: 28886476
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sorafenib-Sunitinib Sequence: The Jury Is Out.
    Albiges L; Escudier B
    Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
    [No Abstract]   [Full Text] [Related]  

  • 75. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.
    Chittoria N; Haddad H; Elson P; Tannir NM; Wood LS; Dreicer R; Garcia JA; Rini BI; Jonasch E
    BMC Cancer; 2016 Mar; 16():254. PubMed ID: 27026229
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
    Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T
    Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Axitinib for the treatment of metastatic renal cell carcinoma.
    Parekh H; Griswold J; Rini B
    Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.
    Guida A; Albiges L; Derosa L; Loriot Y; Massard C; Fizazi K; Escudier B
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1081-e1088. PubMed ID: 28888866
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Ren M; Dutcus C; Larkin J
    Lancet Oncol; 2016 Jan; 17(1):e4-5. PubMed ID: 26758760
    [No Abstract]   [Full Text] [Related]  

  • 80. [Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
    Kobayashi H; Ashikari A; Namitome R; Yagi Y; Kohno Y; Nishiyama T; Saito S
    Nihon Hinyokika Gakkai Zasshi; 2012 Sep; 103(5):660-4. PubMed ID: 23342925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.